GlassScriptPhysician profile
Magy Eskander
NPI 1982047643
$3,176.14
in general payments reported to CMS, 2019-2025
27 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $128 · 2021: $449 · 2022: $613 · 2023: $445 · 2024: $1,136 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $372.27 | 2019-2024 | Clareon, Argos, Rocklatan |
| Biotissue Holdings INC. | $368.65 | 2022-2025 | |
| Abbvie INC. | $271.40 | 2022-2024 | |
| New World Medical,INC. | $259.77 | 2022-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Allergan, INC. | $237.32 | 2020-2022 | |
| Oyster Point Pharma, INC. | $197.07 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $165.49 | 2019-2021 | |
| Ocular Therapeutix, INC. | $159.58 | 2022-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $132.77 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $121.11 | 2022 | |
| Coherus Oncology, INC. | $118.76 | 2023-2024 | |
| Sandoz INC. | $102.01 | 2024-2025 | Cimerli |
| Apellis Pharmaceuticals, INC. | $97.47 | 2024 | Syfovre |
| Rayner Intraocular Lenses Limited | $77.61 | 2023-2024 | Omidria, Rayone Spheric, Rayone Emv |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $76.40 | 2019 | |
| Mallinckrodt Hospital Products INC. | $45.80 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.75 | 2019-2020 | |
| Rxsight INC | $39.73 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Omeros Corporation | $33.39 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $31.29 | 2024 | Vyzulta, Xiidra, Miebo |
| Regeneron Healthcare Solutions, INC. | $27.40 | 2025 | Eylea Hd, Eylea |
| Thea Pharma INC. | $18.87 | 2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $16.81 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $15.80 | 2024 | |
| Glaukos Corporation | $12.94 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magy Eskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.